Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing hormone agonist administration

European Journal of Endocrinology

Volumn 137, Issue 2, 1997, Pages 167-171

  Taga, Michiyoshi ^a   Minaguchi, Hiroshi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; COLLAGEN TYPE 1; NAFARELIN;

ADULT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONAL THERAPY; HUMAN; INTRANASAL DRUG ADMINISTRATION; LEIOMYOMA; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN SECRETION; PROTEIN URINE LEVEL;

ADULT; AMINO ACIDS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; BUSERELIN; COLLAGEN; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONES; HUMANS; LEIOMYOMA; MIDDLE AGED; NAFARELIN; UTERINE NEOPLASMS;

EID: 0030878273     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1370167     Document Type: Article

References (10)

1. Taga M & Minaguchi H. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstetrica et Gynaecologies Scandinavica 1996 75 162-165.
2. Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J & Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. Journal of Clinical Endocrinology and Metabolism 1988 67 701-706.
3. Finkelstein JS, Klibanski AK, Schaefer EH, Hornstein MD, Schiff I & Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. New England Journal of Medicine 1994 331 1618-1623.
4. Garnero P, Gineyts E, Riou JP & Delmas PD, Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. Journal of Clinical Endocrinology and Metabolism 1994 79 780-785.
5. Bonde M, Quist P, Fledelius C, Riis BJ & Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clinical Chemistry 1994 40 2022-2025.
6. Marshall LA, Cain DF, Dmowski WP & Chesnut III CH. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstetrics and Gynecology 1996 87 350-354.
7. Uebelhart D, Gineyts E, Chapuy MC & Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Mineral 1990 8 87-96.
8. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK et al. Monitoring bone resorption in early post menopausal women by an immunoassay for cross-linked collagen peptides in urine. Journal of Bone and Mineral Research 1994 9 135-142.
9. Hanson DA, Weis MAE, Bollen A-M. Maslan SL, Singer FR & Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. Journal of Bone and Mineral Research 1992 7 1251-1258.
10. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcified Tissue International 1994 54 26-29.